Bioxytran, Inc.
BIXT · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | -$0 | -$0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $0 | $1 | $1 | $2 |
| G&A Expenses | $1 | $2 | $1 | $2 |
| SG&A Expenses | $1 | $3 | $1 | $2 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $1 | $0 | $0 | $0 |
| Operating Expenses | $2 | $4 | $2 | $4 |
| Operating Income | -$2 | -$4 | -$2 | -$4 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$0 | -$1 | -$1 | -$0 |
| Pre-Tax Income | -$2 | -$4 | -$3 | -$5 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$2 | -$4 | -$2 | -$4 |
| % Margin | – | – | – | – |
| EPS | -0.017 | -0.032 | -0.021 | -0.041 |
| % Growth | 46.4% | -49.1% | 47.7% | – |
| EPS Diluted | -0.017 | -0.032 | -0.021 | -0.041 |
| Weighted Avg Shares Out | 139 | 134 | 115 | 106 |
| Weighted Avg Shares Out Dil | 139 | 134 | 115 | 106 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $1 | $1 | $1 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $4 |
| EBITDA | -$2 | -$4 | -$2 | $0 |
| % Margin | – | – | – | – |